Thymosin Alpha-1 vs TB-500

Side-by-side comparison of Thymosin Alpha-1, TB-500 — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute Thymosin Alpha-1 Thymosin Alpha-1 (Tα1) Longevity TB-500 Thymosin Beta-4 Synthetic Analogue Recovery
Basics
Molecular type Thymic PeptideThymic Peptide Analogue
Amino acids 2843
Molecular weight 3,108.4 Da4,921 Da
Half-life ~2 hoursLong-acting (days)
Route(s) SubcutaneousSubcutaneous, Intramuscular
Mechanism & Research
Primary mechanism Thymosin Alpha-1 stimulates T-cell differentiation and maturation, particularly enhancing T-helper cell (Th1) responses. This drives improved cell-mediated immunity — the arm of the immune system responsible for clearing… TB-500's primary mechanism involves binding to G-actin (monomeric actin) through its conserved LKKTETQ sequence. By sequestering actin, it regulates cytoskeletal dynamics in ways that promote cell migration — a critical …
Research status Research Compound Research Compound
Evidence summary Thymosin Alpha-1 has extensive human clinical data from its regulatory approval in Asia and Europe for viral hepatitis and cancer adjunct therapy. Longevity applications build on this established safety and immune-modula… TB-500 research spans cardiac regeneration, wound healing, hair follicle regeneration, and musculoskeletal repair. Most data is preclinical. Phase 1/2 trials with native Thymosin Beta-4 for cardiac indications have been …
Protocol & Dosing
Typical dose 1.6 mg per injection (standard clinical dose)5–10 mg per injection
Frequency 2x per week for 6–12 weeks2x per week (loading), then weekly
Duration 6–12 weeks4–8 weeks
Timing Any time of dayNo specific timing requirement
Safety
Common side effects
  • Injection site redness
  • Mild flu-like symptoms (first injection)
  • Fatigue (transient)
  • Injection site reaction
  • Mild fatigue (transient)
  • Headache
  • Lethargy in first days
Contraindications
  • Active autoimmune disease (immune stimulation risk)
  • Post-organ transplant (immunosuppression may be reversed)
  • Known allergy to thymic peptides
  • Active cancer (angiogenic activity)
  • Pregnancy
  • Platelet disorders or anticoagulant use
Anti-doping Not Prohibited Prohibited (WADA S2)
Deeper reading
Related peptides Epithalon, TB-500, LL-37 BPC-157, GHK-Cu, Thymosin Alpha-1
Full profile Read full Thymosin Alpha-1 profile → Read full TB-500 profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.